Results 51 to 60 of about 65,038 (202)

The malignant transformation potential of the oncogene STYK1/NOK at early lymphocyte development in transgenic mice

Biochemistry and Biophysics Reports
B-cell Chronic Lymphocytic Leukemia (B-CLL) is a malignancy caused by the clonal expansion of mature B lymphocytes bearing a CD5+CD19+ (B1) phenotype. However, the origin of B-CLL remains controversial. We showed previously that STYK1/NOK transgenic mice
Yin Yang, Li Liu, Haley O. Tucker
doaj   +1 more source

CD14 as a potential prognostic factor and Bcl-2 as a therapeutic target in egyptian B-Cell chronic lymphocytic leukemia patients

Journal of Applied Hematology, 2019
INTRODUCTION: B-cell chronic lymphocytic leukemia (B-CLL) is a unique lymphoproliferative disorder that scarcely occurs under the age of 40. B-CLL represents a neoplastic disorder caused primarily by defective programmed cell death and accompanied by a ...
Mohamed Mahmoud El-Khawanky, Mohamed Hanfy Morsy, Amina Mohamed Elnaggar, Ola Ali Hussin, Mohga Mahmoud Zaewer, Naglaa Ali Khalifa   +5 more
doaj   +1 more source

A Case of Chronic Lymphocytic Leukemia in Two Brothers

Bezmiâlem Science, 2017
Monoclonal B-cell lymphocytosis is accepted as an important risk factor for developing lymphocytosis familial chronic lymphocytic leukemia (CLL) but does not meet the criteria for B-cell lymphoproliferative disease, and patients with
İlhami GÜLTEPE, Tuba ÖZKAN, Güven ÇETİN   +2 more
doaj   +1 more source

Anti-Tumor Necrosis Factor-α Therapy in the Management of Psoriasis and B-Chronic Lymphocytic Leukemia

Case Reports in Dermatology, 2011
Psoriasis is a chronic immunologically-based inflammatory skin disease. B-chronic lymphocytic leukemia (B-CLL) is a form of leukemia characterized by the slow and progressive accumulation of monoclonal CD5+ B lymphocytes in peripheral blood, bone marrow,
Anna Balato, Serena Lembo, Teresa Cirillo, Matteo Megna, Annunziata Raimondo, Luisa Di Costanzo   +5 more
doaj   +1 more source

A Detailed Analysis of Parameters Supporting the Engraftment and Growth of Chronic Lymphocytic Leukemia Cells in Immune-Deficient Mice

Frontiers in Immunology, 2021
Patient-derived xenograft models of chronic lymphocytic leukemia (CLL) can be created using highly immunodeficient animals, allowing analysis of primary tumor cells in an in vivo setting.
Piers E. M. Patten, Piers E. M. Patten, Gerardo Ferrer, Shih-Shih Chen, Jonathan E. Kolitz, Jonathan E. Kolitz, Kanti R. Rai, Kanti R. Rai, Steven L. Allen, Steven L. Allen, Jacqueline C. Barrientos, Jacqueline C. Barrientos, Nikolaos Ioannou, Alan G. Ramsay, Nicholas Chiorazzi, Nicholas Chiorazzi, Nicholas Chiorazzi   +16 more
doaj   +1 more source

Role of the atypical chemoattractant receptor CRAM in regulating CCL19 induced CCR7 responses in B-cell chronic lymphocytic leukemia [PDF]

, 2010
Background The non-signalling chemokine receptors, including receptors DARC, D6 and CCX-CKR, have recently been shown to be involved in chemokine clearance and activity regulation. The human chemokine receptor CRAM (also known as HCR or CCRL2)
David J Clark, Julie Catusse, Katja Zirlik, Maike V Buchner, Mareike Groch, Marion Leick, Meike Burger   +6 more
core   +2 more sources

Germinal center trajectories and transcriptional signatures define CLL subtypes and their pathway regulators.

PLoS ONE
Chronic lymphocytic leukemia (CLL) is divided into unmutated (UM-CLL) and mutated (M-CLL) subtypes depending on somatic hypermutation (SHM) frequency in their immunoglobulin heavy chain V (IGHV) region. We previously demonstrated that CD27bright memory B
Ahmed Mohamed, Luca Giudice, José Basílio, Sabina Barresi, Pradeep Kumar Kopparapu, Vanda Friman, Marco Tartaglia, Tarja Malm, Andreas Tilevik, Ola Grimsholm   +9 more
doaj   +1 more source

Pathogen‐specific B‐cell receptors drive chronic lymphocytic leukemia by light‐chain‐dependent cross‐reaction with autoantigens

EMBO Molecular Medicine, 2017
Several lines of evidence indirectly suggest that antigenic stimulation through the B‐cell receptor (BCR) supports chronic lymphocytic leukemia (CLL) development.
Nereida Jiménez de Oya, Marco De Giovanni, Jessica Fioravanti, Rudolf Übelhart, Pietro Di Lucia, Amleto Fiocchi, Stefano Iacovelli, Dimitar G Efremov, Federico Caligaris‐Cappio, Hassan Jumaa, Paolo Ghia, Luca G Guidotti, Matteo Iannacone   +12 more
doaj   +1 more source

Marked efficacy of Rituximab in multifocal motor neuropathy associated with chronic lymphocytic leukemia [PDF]

, 2016
The authors describe a patient who presented a multifocal motor neuropathy (MMN) associated with a high anti-ganglioside antibody (anti-GM1 and anti-GD1) titer at the clinical onset of a B-cell chronic lymphocytic leukemia (B-CLL). Immunomodulation (IVIg
Antonella Di, Pasquale, Antonini, Giovanni, Bucci, Elisabetta, DE SANTIS, Tiziana, Fionda, Laura, Mauro, Francesca Romana, Stefania, Morino   +6 more
core  

Antitumour effects of single or combined monoclonal antibodies directed against membrane antigens expressed by human B cells leukaemia [PDF]

, 2011
International audienceBackgroundThe increasing availability of different monoclonal antibodies (mAbs) opens the way to more specific biologic therapy of cancer patients. However, despite the significant success of therapy in breast and ovarian carcinomas
André, Pierre-Alain, Berthou, Christian, Bologna, Luca, Boumsell, Laurence, Buchegger, Franz, Cérutti, Martine, Delaloye, Angelika,, Golay, Josee, Kadouche, Jean, Kosinski, Marek, Loisel, Séverine, Mach, Jean-Pierre, Viertl, David   +12 more
core   +5 more sources